Lysophosphatidic acid induces neointima formation through PPARgamma activation. - Wikidata - awgldk - TriplyDB

Lysophosphatidic acid induces neointima formation through PPARgamma activation.

Lysophosphatidic acid induces neointima formation through PPARgamma activation.

http://www.wikidata.org/entity/Q36402330

about

PPARs and the cardiovascular system A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells Lysophosphatidic acid activates peroxisome proliferator activated receptor-γ in CHO cells that over-express glycerol 3-phosphate acyltransferase-1 alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure.Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand Phosphatidate degradation: phosphatidate phosphatases (lipins) and lipid phosphate phosphatases.Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation.Lysophosphatidic acid in atherosclerotic diseases Aiming drug discovery at lysophosphatidic acid targets.Lysophosphatidic acid-operated K+ channels.US28 is a potent activator of phospholipase C during HCMV infection of clinically relevant target cells Lysophosphatidic acid suppresses endothelial cell CD36 expression and promotes angiogenesis via a PKD-1-dependent signaling pathway.Vascular involvement in systemic sclerosis (scleroderma).Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling.Pathogenesis of Systemic Sclerosis.Lpa2 is a negative regulator of both dendritic cell activation and murine models of allergic lung inflammation.Lysophosphatidic acid causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells.Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic phosphatidic acid.The early- and late stages in phenotypic modulation of vascular smooth muscle cells: differential roles for lysophosphatidic acid PPAR γ Networks in Cell Signaling: Update and Impact of Cyclic Phosphatidic Acid.Identification of non-lipid LPA3 antagonists by virtual screening.PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?Lysophospholipid interactions with protein targets.Roles of lysophosphatidic acid in cardiovascular physiology and disease Regulation of the LPA2 receptor signaling through the carboxyl-terminal tail-mediated protein-protein interactions Therapeutic potential of autotaxin/lysophospholipase d inhibitors.Sphingosine kinase is induced in mouse 3T3-L1 cells and promotes adipogenesis Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling.Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.Lipid phosphate phosphatases and signaling.Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling.Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques.The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation.Regulation of blood and vascular cell function by bioactive lysophospholipids.The effects of aspirin and fish oil consumption on lysophosphatidylcholines and lysophosphatidic acids and their correlates with platelet aggregation in adults with diabetes mellitus.Arguing the case for the autotaxin-lysophosphatidic acid-lipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis.Peroxisomes: a nexus for lipid metabolism and cellular signaling.

P2860

Q24642728-920A3AEE-42A3-469E-ADF5-C7F2A63166C5 Q24678857-B2593575-B930-4AF2-913C-D09E8DAE62F4 Q28740882-81785AB7-6D3A-46C0-8028-317EB3788752 Q30435432-DB93D7BD-B2AC-41A4-8DA0-B2A17C9EC977 Q30440269-005FBCF3-AAF5-4146-B23A-9FD46280541B Q33849597-269F0CD6-FB0A-4A75-BEFC-B37131323DCD Q33871978-3958C9D1-C905-46ED-B866-15BF2E535BA2 Q33882610-C698D9D8-C9C5-44CE-98F4-7C44A3513B61 Q34273486-B5003D0C-2D64-43B1-8294-D0F6930A9831 Q34339759-C8352E3B-86F5-40FE-ADDC-B27F0941A566 Q34372355-76559D61-CE76-44BC-806A-BE6148999D5F Q34500430-5E14F989-B8EF-4918-87FE-668D84595539 Q35037444-994EBAB8-6CB4-4A9D-AB21-88BEB691405C Q35557424-FEC9B8EA-CBA0-4140-A577-40006D4B1A6C Q35621592-8DFC8DE7-785E-4150-B71F-94771E276FAB Q35693212-FB09431C-9F35-4B09-9884-78DE2D8E38EB Q35883942-6319AF85-EF09-40AC-BA87-165229EE83E9 Q35907288-247A5C59-BC07-477F-A291-337E84A685E7 Q36246883-FEC1CFE2-260F-423D-890A-87DA3017696F Q36246905-DC667418-4F25-4E1D-81B9-75C82AD66E5F Q36637912-21E6ED6B-0AC9-4D85-B9FF-B727A5D669B4 Q36789822-DFFC2213-942B-4594-A8E1-A3BB2F2005D5 Q36889164-11E2145D-AFCE-4E0C-B41A-497CA495E01D Q36930850-7F55A2DA-2BFB-4500-8322-8AB9F90A8F63 Q36948520-2124C3EF-8448-4832-B73A-D6BFA1724C0D Q36951961-F9E24521-DF3E-4DE1-B394-47D9501A4D3D Q37049044-BB9A2E29-3ABA-42F7-8278-3154A2C7A045 Q37130779-92BB1751-214B-417E-9790-416D13C71008 Q37139302-25572628-5B2A-4E25-B873-FE5B8C5502D0 Q37142814-07A86293-10BC-49FD-9DE5-0012F1FBE673 Q37173179-AB536C08-94AC-41A4-BE73-A7EF7918384C Q37289059-BA57AB5F-F931-4919-8BEF-FB479064B9B3 Q37384489-DC5C3F8E-ECA7-40A1-9A3A-20A8D1F6AEA6 Q37411594-012C50FD-47DE-43A9-BB34-02435AB2909F Q37416056-661209BE-C6ED-4E09-B2C1-E5DE4A1872EC Q37527792-85CACCD7-1AB4-42BF-89DB-5B2CB5E26477 Q37561419-0B5C6032-23C2-438C-AE60-31471082EDF1 Q37612293-D7B378DD-173A-455E-AD70-1B39C66B4E20 Q37620329-782395E7-044A-40B3-B439-3C7975A9F6BC Q37633445-59456D95-EFE6-4B3A-904D-E249B616BCC5

P2860

Lysophosphatidic acid induces neointima formation through PPARgamma activation.

http://www.wikidata.org/entity/Q36402330

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Lysophosphatidic acid induces neointima formation through PPARgamma activation.

@ast

Lysophosphatidic acid induces neointima formation through PPARgamma activation.

@en

type

label

Lysophosphatidic acid induces neointima formation through PPARgamma activation.

@ast

Lysophosphatidic acid induces neointima formation through PPARgamma activation.

@en

prefLabel

Lysophosphatidic acid induces neointima formation through PPARgamma activation.

@ast

Lysophosphatidic acid induces neointima formation through PPARgamma activation.

@en

P1433

Q36402330-7380F47F-39FE-4099-BC1B-1B751481A818

P1476

Q36402330-BD1EFA5D-F413-4B39-8078-2B55A01E2E17

P2093

Q36402330-03A97BA1-6E2D-4A1E-BBD2-36EF67FDC1DE

Q36402330-2ED653E0-CB1D-4DE4-8C3C-96FE26DF7593

Q36402330-2F60DE37-59C7-4397-A2E6-71DA4DDD90B0

Q36402330-5E56A47E-F97C-4463-98E9-FCFF9614BB10

Q36402330-61E9E6A0-1820-4D43-934A-5E5FFE468423

Q36402330-6E8A8B0B-2B75-48DB-A79C-274601FCE31F

Q36402330-77570297-D4BE-4525-B08E-0039F0BA8026

Q36402330-77999279-7D69-401C-9422-8C1FA350330B

Q36402330-79C79311-008D-4D8C-89C2-B99E321EC902

Q36402330-7F3693EA-B97F-4C71-A085-67C0539E516D

P2860

Q36402330-06F29F84-D31B-4C98-9E87-EC185BA54E95

Q36402330-0AD14976-C691-45C6-9FE1-5538A0996114

Q36402330-3CE9AAD2-7092-484C-AA52-167220D3AA7B

Q36402330-3D77A741-A20C-4C75-B3AA-924AD3A79D44

Q36402330-55E1D7C8-F412-4DF5-8504-9DA7F831BF85

Q36402330-5ADF97B5-B77A-4CB0-88D4-2F18589C9638

Q36402330-5D0B94B0-BEBB-4F43-A5CF-FDE5F41C5F72

Q36402330-5FC38E8A-2BBA-417C-8A51-CB46592D76EB

Q36402330-604AF7DB-6242-45F5-9340-759F9846C357

Q36402330-65F1BFB9-D7C9-42E8-9763-58DDDAEBD66E

P304

Q36402330-57C158E7-1B88-4E76-9469-F17C1D22345F

P31

Q36402330-EC589056-ADBE-460D-8A34-9BE16A6F0503

P356

Q36402330-43EA9A37-7C0A-42D5-B109-07E1290A3DDD

P407

Q36402330-C6EC00AA-ED5A-4A62-9807-CB44BE27A33D

P433

Q36402330-51D02FD8-3F28-4393-8864-C2F679432621

P478

Q36402330-626B7034-D354-4845-A5F6-B785504CE5DC

P50

Q36402330-71F2385D-82AC-4A13-B4D6-BD992E94FB2C

P577

Q36402330-46F69980-16C7-48A4-8E3A-7B6374A8236B

P698

Q36402330-C6C4E806-5437-41A3-864A-38FA50544C83

P932

Q36402330-1220282A-3AC0-49C7-8CAF-B45624DF92ED

P356

P1433

Journal of Experimental Medicine

P1476

Lysophosphatidic acid induces neointima formation through PPARgamma activation

@en

P2093

Chunxiang Zhang

http://www.w3.org/2001/XMLSchema#string

Daniel L Baker

http://www.w3.org/2001/XMLSchema#string

Gabor Tigyi

http://www.w3.org/2001/XMLSchema#string

Glenn D Prestwich

http://www.w3.org/2001/XMLSchema#string

Gopal K Marathe

http://www.w3.org/2001/XMLSchema#string

Hoe-Sup Byun

http://www.w3.org/2001/XMLSchema#string

Leonard R Johnson

http://www.w3.org/2001/XMLSchema#string

Louisa Balazs

http://www.w3.org/2001/XMLSchema#string

Natalia Makarova

http://www.w3.org/2001/XMLSchema#string

Robert Bittman

http://www.w3.org/2001/XMLSchema#string

P2860

Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids

Atherosclerosis

Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors

Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family

Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: modulation of cellular activity of sphingosine 1-phosphate

Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime

Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors

Inflammation in atherosclerosis

Biologically active oxidized phospholipids.

Atherosclerosis is an inflammatory disease.

P304

763-774

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20031619

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

199

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15007093

http://www.w3.org/2001/XMLSchema#string

P932

2212723

http://www.w3.org/2001/XMLSchema#string